Home LiteratureArticle Details
PMID: 19856521 Published · ppublish English Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

Vaccine ·Vol. 27 ·No. 45 ·2009-10-23 ·Pages 6284-90

Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, Gillard P, Jilg W

Abstract

Priming a population with a pre-pandemic vaccine is being considered to maximize the response upon subsequent vaccination with a true pandemic vaccine more closely matched to the causative pandemic strain. The present study explored this prime-boost concept by evaluating different primary schedules with the pre-pandemic A/Vietnam/1194/2004(NIBRG-14) vaccine, containing 3.75 microg of HA, followed by a 6-month booster with a vaccine formulated with 3.75 microg HA of either the same strain or with A/Indonesia/05/2005(IBCDC-RG2), a heterologous strain from a different clade. In this multicentre, open, randomized study (NCT00430521) we measured immune responses in four groups (N = 48-60) of adults aged 18-60 years who received a single booster administration of either A/Indonesia/05/2005 or A/Vietnam/1194/2004 vaccine 6 months after a 1- or 2-dose (given 21 days apart) primary vaccination with A/Vietnam/1194/2004. All prime-boost schedules assessed induced early (7 days post-booster) humoral responses that met regulatory acceptance criteria. Two doses of A/Vietnam/1194/2004 given 6 months apart achieved equivalent homologous seroprotection after the second vaccination (89.6%), when compared to two doses given 21 days apart (92.7-93.2%). Remarkably, two doses of A/Vietnam/1194/2004 given 6 months apart induced a higher cross-reactive seroprotection against A/Indonesia/05/2005 (83.3%) when compared to two doses given 21 days apart (41.5-54.5%). A 6-month A/Indonesia/05/2005 booster dose after one primary dose of A/Vietnam/1194/2004 vaccine induced 92.5% seroprotection against A/Indonesia/05/2005 and 98.1% against A/Vietnam/1194/2004. Since a single booster 6 months after one primary dose of AS03-adjuvanted vaccine induces strong and rapid seroprotective immune response against both homologous and heterologous H5N1 strains, these results might have important implications for public health strategy aiming to organize vaccination campaigns with pre-pandemic vaccines.

MeSH Terms
Adjuvants, Immunologic/administration & dosage Adolescent Adult Antibodies, Viral/blood Cross Protection Female Hemagglutination Inhibition Tests Humans Immunity, Humoral Immunization, Secondary Influenza A Virus, H5N1 Subtype/immunology Influenza Vaccines/administration & dosage,immunology Influenza, Human/immunology,prevention & control Male Middle Aged Young Adult
Chemicals
Adjuvants, Immunologic Antibodies, Viral Influenza Vaccines
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Schwarz Tino F
Stiftung Juliusspital, Körperschaft des öffentlichen Rechts, Juliuspromenade 19, 97070 Würzburg, Germany. t.schwarz@juliusspital.de
Horacek Thomas
Knuf Markus
Damman Hanns-Gerd
Roman François
Dramé Mamadou
Gillard Paul
Jilg Wolfgang
Article Info
Journal
Vaccine
Abbr.
Vaccine
ISSN
1873-2518
Published
2009-10-23
Pages
6284-90
Language
English
Region
Netherlands
NLM ID
8406899
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com